Aarti Pharmalabs Limited · NSE:AARTIPHARM

Aarti Pharmalabs — Shareholder Meeting (September 2025)

12 slides from Aarti Pharmalabs's shareholder meeting presentation, Sep 23, 2025

  1. Slide 1: Exchange filing cover letter: Investor Presentation

    September 23, 2025 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai - 400 001 G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 SCRIP CODE:

  2. Slide 2: 6th Annual General Meeting, Sep 2025

    6 Annual General Meeting th SEP 2025

  3. Slide 3: Snapshot

    SNAPSHOT 25 Years of Pharmaceutical Excellence 220+ Products 500+ Global Clients State-of-the-art 3 R&D facilities 58 Patents Filed 50+ Export Countries Manufacturing 6 Units 50 US DMF 2,100+ Employees 3 USFDA Units 31 CEP Global 15-20% Market Share 0.19x Net Debt/Equity A+ Credit rating in Xanthine

  4. Slide 4: Company Overview

    COMPANY OVERVIEW STANDALONE REVENUE (INR Mn) • Aarti Pharmalabs Limited (APL) is part of the Aarti group – a diversified chemical conglomerate with & EBITDA MARGINS (%) group turnover of INR 130+ bn (FY25) 17,714 • Globally recognized manufacturer of generic API, Xanthine derivatives and a leading p

  5. Slide 5: Key Milestones

    KEY MILESTONES • 2024 Started 21 MW solar power project at Akola, Maharashtra • Expansion of semi-commercial production block at Vapi 2022 • Expanded block for CSD in Vapi and API in Tarapur units • Acquired land at Atali for future growth 12 • Successfully demerged the pharmaceutical business of Aa

  6. Slide 6: Key Business Segments

    KEY BUSINESS SEGMENTS QUARTERLY REVENUE BREAK-UP 34.3% 43.5% 52.6% Xanthine Derivatives & Allied Products 38.8% API & Intermediates 43.6% 36.1% 26.9% CDMO/CMO 11.3% 12.9% FY24 FY25 Q4-FY25 CDMO/CMO API & Intermediates Xanthine derivatives

  7. Slide 7: Annual Consolidated Income Statement

    ANNUAL CONSOLIDATED INCOME STATEMENT PARTICULARS (INR Mn) FY25 FY24 Y-O-Y Operational Revenue 21,151 18,526 14.2% Operating Expenses 16,507 14,666 12.6% EBITDA 4,644 3,860 20.3% EBITDA Margin (%) 21.96% 20.84% 112 Bps Depreciation and Amortisation 869 732 18.7% Finance costs 269 172 56.4% Other Inco

  8. Slide 8: Historical Consolidated Income Statement

    HISTORICAL CONSOLIDATED INCOME STATEMENT PARTICULARS (INR Mn) 9M-FY22 FY23 FY24 FY25 Operational Revenue 11,999 19,452 18,526 21,151 Total Expenses 9,929 16,031 14,666 16,507 EBITDA 2,070 3,421 3,860 4,644 EBITDA Margins (%) 17.25% 17.59% 20.84% 21.96% Depreciation and Amortisation 421 625 732 869 F

  9. Slide 9: Annual Standalone Income Statement

    ANNUAL STANDALONE INCOME STATEMENT PARTICULARS (INR Mn) FY25 FY24 Y-O-Y Operational Revenue 17,714 15,021 17.9% Operating Expenses 13,449 11,560 16.3% EBITDA 4,265 3,461 23.2% EBITDA Margin (%) 24.08% 23.04% 104 Bps Depreciation and Amortisation 791 660 19.8% Finance costs 256 166 54.2% Other Income

  10. Slide 10: Historical Standalone Income Statement

    HISTORICAL STANDALONE INCOME STATEMENT PARTICULARS (INR Mn) 9M-FY22 FY23 FY24 FY25 Operational Revenue 9,410 15,112 15,021 17,714 Total Expenses 7,613 12,028 11,560 13,449 EBITDA 1,797 3,084 3,461 4,265 EBITDA Margins (%) 19.10% 20.41% 23.04% 24.08% Depreciation and Amortisation 372 558 660 791 Fina

  11. Slide 11: Consolidated Financial Highlights

    CONSOLIDATED FINANCIAL HIGHLIGHTS OPERATIONAL INCOME (INR Mn) EBITDA (INR Mn) & EBITDA PAT (INR Mn) & PAT MARGINS (%) MARGINS (%) 4,644 21,151 19,452 3,860 2,724 18,526 3,421 2,169 1,935 11,999 2,070 1,223 20.84% 21.96% 17.25% 17.59% 12.88% 10.19% 11.71% 9.95% 9M-FY22 FY23 FY24 FY25 9M-FY22 FY23 FY2

  12. Slide 12: Thank You

    THANK YOU AARTI PHARMALABS LIMITED

Aarti Pharmalabs — Shareholder Meeting (September 2025) on 6ix